modelChlorzoxazone
Extends from Pharmacolibrary.Drugs.ATC.M.M03BB03.
Information
| name: | Chlorzoxazone | |
| ATC code: | M03BB03 | route: | oral |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 0.91 | L |
| clearance: | 3.9 | ml/min/kg |
| other parameters in model implementation | ||
Chlorzoxazone is a centrally acting muscle relaxant used to relieve pain and discomfort caused by muscle spasms. It is often prescribed in combination with other treatments for musculoskeletal conditions. While once commonly used, its presence on the market has diminished in some countries due to concerns over hepatotoxicity, but it is still approved and marketed in several regions.
Pharmacokinetics
Pharmacokinetics reported in healthy adult volunteers, both male and female.
References
de Vries, JD, et al., & Hoener, BA (1994). Variability in the disposition of chlorzoxazone. Biopharmaceutics & drug disposition 15(7) 587–597. DOI:10.1002/bdd.2510150706 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7849234
Li, L, & Zhang, Y (1998). [Determination of chlorzoxazone and its metabolite 6-hydroxychlorzoxazone in plasma by HPLC and their pharmacokinetics]. Yao xue xue bao = Acta pharmaceutica Sinica 33(10) 731–736. PUBMED:https://pubmed.ncbi.nlm.nih.gov/12016924
Raucy, JL, et al., & Carpenter, SP (1999). CYP2E1 expression in human lymphocytes from various ethnic populations. Alcoholism, clinical and experimental research 23(12) 1868–1874. PUBMED:https://pubmed.ncbi.nlm.nih.gov/10630604
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)